|Bid||82.12 x N/A|
|Ask||86.33 x N/A|
|Day's range||83.65 - 84.74|
|52-week range||73.79 - 94.77|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||26.24|
|Forward dividend & yield||3.20 (3.78%)|
|Ex-dividend date||09 Mar 2023|
|1y target est||N/A|
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with pre
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.